Can a simple HPV test replace colposcopy for cervical cancer Follow-Up?

NCT ID NCT01051895

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two ways to check for returning cervical pre-cancer after treatment: the standard colposcopy exam versus a high-risk HPV DNA test. Over 2,200 women who were treated for high-grade cervical lesions will be randomly assigned to one of the two follow-up methods. The goal is to see which approach is more sensitive at detecting persistent or recurrent disease, potentially making follow-up care simpler and more accessible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

high risk HPV DNA testing

What this could lead to

If successful, this could show that a simple HPV test is better than a colposcopy for catching returning cervical pre-cancer, potentially making follow-up easier and more accurate.

What could go wrong

This is a diagnostic comparison, not a treatment. The results may not change practice if HPV testing proves less effective or too costly. Also, the study is observational in nature, so it cannot prove that one strategy improves long-term health outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE CERVICAL INTRA-EPITHELIAL NEOPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma in situ cervical intraepithelial neoplasia cervical intraepithelial neoplasia grade 2/3 uterine cervix carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre de recherche du CHUM

    Montreal, Quebec, H2X 0A9, Canada